Hans Keirstead

Hans Keirstead is a medical scientist and entrepreneur specializing in stem cell research. He ran as a Democrat to represent California's 48th district in the US Congress in the 2018 elections, but he was defeated in the primary by Harley Rouda.

Keirstead announced in June 2017 that he would run for Congress as a Democrat, challenging a seat held by Dana Rohrabacher in California's 48th Congressional District. In a 2018 interview with ABILITY Magazine, Keirstead said "We don’t have anyone [in Washington] with a broad, deep understanding of the healthcare system, for example, not a one. 435 members, and there’s no one there with a broad, deep understanding of what is 20 percent of our economy. We need that." He conceded the Democratic Party primary to Harley Rouda on Sunday, June 24, 2018 after a very close race. His campaign appears to have been targeted by a cyberattack.

In 2014, he sold a stem-cell company in a deal worth $124 million.

In 2013, Keirstead took a leave of absence from UC Irvine to conduct tests in the private sector. He joined California Stem Cell, Inc., also based in Irvine, as its president and CEO. His first focus after the leave of absence was trials for targeting skin cancer cells using stem cells from the cancer itself to train the immune system.

In 2010, Geron Corporation began the world's first clinical trial of human embryonic stem cell treatment for spinal cord injuries, based on the research of Keirstead's team at UC Irvine. However, the trials ended after a year due to lack of funds.

In 2004, Keirstead publicly supported California Proposition 71, which aimed to authorize three billion dollars for stem cell research for a newly created California Institute for Regenerative Medicine. During the debate he released a video of how he could restore mobility to paralyzed rats using his stem cell research. Keirstead was criticized at the time, because the procedure had yet to be published in a peer reviewed journal, but it subsequently published the following year in the Journal of Neuroscience. The procedure was reproduced by three other labs by 2006, confirming that cells engineered to make myelin can help restore damaged areas of the spinal cord.

Keirstead has advised U.S. Senators and members of Congress on health care and biotechnology. He testified on the state's biotech industry to the California State Senate in 2002 amidst a national debate about stem cell laws and policy in the United States.

In 2000, Keirstead left his position at the University of British Columbia, where his spinal cord research had been funded by Rick Hansen's charitable foundation. He joined the Reeve-Irvine Research Center at the University of California, Irvine.